Business
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
BOSTON, December 05, 2025--PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data for LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/1c4de0ed92b8acee21f686f905dd9982"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dsSFjz_aB0SaFPKPYe5CjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1c4de0ed92b8acee21f686f905dd9982","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/1hEjyhjQQ4SrjOqe.KUN5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/1c4de0ed92b8acee21f686f905dd9982","width":1200,"height":385}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":271,"url":"https://media.zenfs.com/en/business-wire.com/b5e5f9e5d75e2f3383b027553ff9522c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5p6kztXmY78e5ssrSlIEeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b5e5f9e5d75e2f3383b027553ff9522c","width":480,"height":271}}},{"type":"text","content":"LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially registrational Phase 2 trial","length":236,"tagName":"p","attribs":{}},{"type":"text","content":"Initial median overall survival of 13.2 months observed in the combination cohort at the proposed Phase 2 dose, exceeding expected late-line relapsed/refractory setting survival of <2.5 months; overall survival data at this dose continue to mature with final results expected in 1H 2026","length":289,"tagName":"p","attribs":{}},{"type":"text","content":"Responses observed in patients with high-risk mutations, suggesting potential broad applicability","length":97,"tagName":"p","attribs":{}},{"type":"text","content":"Further details to be shared at the 67th American Society of Hematology (ASH) Annual Meeting","length":92,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, December 05, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a h...